Adenocarcinoma of the Pancreas
60
7
7
36
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
18 trials with published results (30%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.7%
10 terminated out of 60 trials
78.3%
-8.2% vs benchmark
5%
3 trials in Phase 3/4
50%
18 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (60)
Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
Switch Maintenance in Pancreatic
The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer